NCT00221702View on ClinicalTrials.gov

PegIntron Versus IntronA in CMAJCC Stage II (EADO 2001/CMII Trial)

PHASE3CompletedINTERVENTIONAL

Enrollment

898

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions

MelanomaNeoplasm Metastasis

Interventions

DRUG

PegIntron

100 mcg SC/week for 36 months

DRUG

intron A

3mui TIWW SC for 18 months

Trial Locations (1)

13274

APHM, dermatology, Marseille

Sponsors

Collaborators (1)

Schering-Plough

All Listed Sponsors

collaborator

Schering-Plough

INDUSTRY

lead

University Hospital, Bordeaux

OTHER